Alnawaz Rehemtulla

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc Imaging proteolytic activity in live cells and animal models
    Stefanie Galban
    Center for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan, United States of America
    PLoS ONE 8:e66248. 2013
  2. pmc Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration
    Alnawaz Rehemtulla
    Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109 2200, USA
    Neoplasia 14:1278-89. 2012
  3. pmc The interconnectedness of cancer cell signaling
    Alnawaz Rehemtulla
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Neoplasia 13:1183-93. 2011
  4. pmc Novel molecular imaging platform for monitoring oncological kinases
    Shyam Nyati
    Department of Radiation Oncology, University of Michigan, Ann Arbor MI 48109 USA
    Cancer Cell Int 10:23. 2010
  5. pmc Neoplasia: the second decade
    Alnawaz Rehemtulla
    University of Michigan, Ann Arbor, MI 48109 2200, USA
    Neoplasia 10:1314-24. 2008
  6. pmc Dinosaurs and ancient civilizations: reflections on the treatment of cancer
    Alnawaz Rehemtulla
    Department of Radiation Oncology and Radiology, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Neoplasia 12:957-68. 2010
  7. ncbi request reprint Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy
    Alnawaz Rehemtulla
    The Department of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI 48109 0582, USA
    Anticancer Res 24:1393-9. 2004
  8. ncbi request reprint Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event
    Alnawaz Rehemtulla
    Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor 48109, USA
    Mol Imaging 3:63-8. 2004
  9. pmc The War on Cancer rages on
    Alnawaz Rehemtulla
    Department of Radiation Oncology and Radiology, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Neoplasia 11:1252-63. 2009
  10. pmc A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation
    A Rehemtulla
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor 48109, USA
    Neoplasia 1:63-70. 1999

Detail Information

Publications86

  1. pmc Imaging proteolytic activity in live cells and animal models
    Stefanie Galban
    Center for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan, United States of America
    PLoS ONE 8:e66248. 2013
    ....
  2. pmc Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration
    Alnawaz Rehemtulla
    Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109 2200, USA
    Neoplasia 14:1278-89. 2012
    ....
  3. pmc The interconnectedness of cancer cell signaling
    Alnawaz Rehemtulla
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Neoplasia 13:1183-93. 2011
    ..This article reflects on historical advances and the role of innovation in the competitive world of grant-sponsored research...
  4. pmc Novel molecular imaging platform for monitoring oncological kinases
    Shyam Nyati
    Department of Radiation Oncology, University of Michigan, Ann Arbor MI 48109 USA
    Cancer Cell Int 10:23. 2010
    ..Such reporter system provides unique insights into the pharmacokinetics and pharmacodynamics of drugs that modulate kinase signaling and have a huge potential in drug discovery, validation, and drug-target interactions...
  5. pmc Neoplasia: the second decade
    Alnawaz Rehemtulla
    University of Michigan, Ann Arbor, MI 48109 2200, USA
    Neoplasia 10:1314-24. 2008
    ..This past year, Neoplasia received a record number of articles for review and has had a 21% increase in the number of published articles...
  6. pmc Dinosaurs and ancient civilizations: reflections on the treatment of cancer
    Alnawaz Rehemtulla
    Department of Radiation Oncology and Radiology, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Neoplasia 12:957-68. 2010
    ..This article reflects on the history of cancer and the progress made following the initiation of the "era of cancer chemotherapy."..
  7. ncbi request reprint Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy
    Alnawaz Rehemtulla
    The Department of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI 48109 0582, USA
    Anticancer Res 24:1393-9. 2004
    ....
  8. ncbi request reprint Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event
    Alnawaz Rehemtulla
    Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor 48109, USA
    Mol Imaging 3:63-8. 2004
    ..It could also be used to study p53 stabilization as a result of inactivating p53 mutations. Such studies will further our understanding of p53's role as the "guardian of the genome" and its function in tumorigenesis...
  9. pmc The War on Cancer rages on
    Alnawaz Rehemtulla
    Department of Radiation Oncology and Radiology, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Neoplasia 11:1252-63. 2009
    ..This article briefly looks back at the progress that has been made in cancer research and compares progress made in other areas of human affliction. While progress has indeed been made, the battle continues to rage on...
  10. pmc A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation
    A Rehemtulla
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor 48109, USA
    Neoplasia 1:63-70. 1999
    ..These results provide a molecular basis for the observation that expression of Bcl-2 or Bcl-X(L) is not a prognostic marker of tumor response to cancer therapy...
  11. pmc A transgenic mouse for imaging caspase-dependent apoptosis within the skin
    Divya Khanna
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    J Invest Dermatol 130:1797-806. 2010
    ..This reporter and transgenic mouse could serve as a unique tool for the study of apoptosis in living cells and animals, especially in the context of skin biology...
  12. pmc A review of the past, present, and future directions of neoplasia
    Alnawaz Rehemtulla
    University of Michigan Medical Center, Ann Arbor, MI 48109 0582, USA
    Neoplasia 7:1039-46. 2005
  13. ncbi request reprint Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy
    Alnawaz Rehemtulla
    University of Michigan School of Medicine, USA
    Mol Imaging 1:43-55. 2002
    ....
  14. pmc Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors
    Victor D Schepkin
    Department of Radiology, Center for Molecular Imaging, University of Michigan Medical School, Ann Arbor, MI 48109 0503, USA
    Magn Reson Imaging 24:273-8. 2006
    ..The results of this study support the continued clinical testing of diffusion MRI for evaluation of early tumor treatment response and demonstrate the complementary insights of sodium MRI for oncology applications...
  15. pmc The parametric response map is an imaging biomarker for early cancer treatment outcome
    Craig J Galban
    Departments of Radiology, University of Michigan, Center for Molecular Imaging, Ann Arbor, USA
    Nat Med 15:572-6. 2009
    ..Even when accounting for baseline rCBV, which is prognostic, PRM(rCBV) proved more predictive of overall survival...
  16. pmc Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma
    Christina Tsien
    Department of Radiation Oncology, University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA
    J Clin Oncol 28:2293-9. 2010
    ..To assess whether a new method of quantifying therapy-associated hemodynamic alterations may help to distinguish pseudoprogression from true progression in patients with high-grade glioma...
  17. ncbi request reprint Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model
    Ming Zhang
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 63:658-63. 2003
    ..Such tumor-specific expression should prove useful in colorectal cancer gene therapy to achieve selective prodrug conversion in tumors...
  18. ncbi request reprint Molecular imaging of Akt kinase activity
    Limin Zhang
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Nat Med 13:1114-9. 2007
    ..The results provide unique insights into the pharmacokinetics and pharmacodynamics of agents that modulate Akt activity, revealing the usefulness of this reporter for rapid dose and schedule optimization in the drug development process...
  19. pmc The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome
    Bradford A Moffat
    Center for Molecular Imaging, Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109 0648, USA
    Neoplasia 8:259-67. 2006
    ..Therefore, The fDM imaging biomarker for early prediction of treatment efficacy can be used in the drug development process...
  20. doi request reprint DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model
    Benjamin A Hoff
    Department of Radiology, University of Michigan, Center for Molecular Imaging, Ann Arbor, MI 48109, USA
    NMR Biomed 25:935-42. 2012
    ..Histological findings were found to support imaging response metrics. In conclusion, kinetic MRI parameters and change in ADC have been found to serve as sensitive and early biomarkers of VEGF-Trap anti-vascular targeted therapy...
  21. pmc Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy
    Joseph N Contessa
    Department of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan, USA
    Clin Cancer Res 16:3205-14. 2010
    ..We therefore investigated the feasibility of blocking NLG in vivo to reduce overexpression of RTKs...
  22. pmc Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival
    Daniel A Hamstra
    University of Michigan, B2A209 UH 1500 East Medical Center Dr, Ann Arbor, MI 48109 0030, USA
    J Clin Oncol 26:3387-94. 2008
    ..Diffusion magnetic resonance imaging (MRI) using a functional diffusion map (fDM) may provide an earlier measure to predict patient survival...
  23. doi request reprint Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas
    Thomas C Kwee
    Department of Radiology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    NMR Biomed 23:179-87. 2010
    ..The observed negative correlation between tumor alpha and tumor DDC requires further investigation...
  24. ncbi request reprint Vascular targeted nanoparticles for imaging and treatment of brain tumors
    G Ramachandra Reddy
    Molecular Therapeutics, Inc, Ann Arbor, MI 48109, USA
    Clin Cancer Res 12:6677-86. 2006
    ..The ability to directly target a therapeutic agent to a tumor site would minimize systemic drug exposure, thus providing the potential for increasing the therapeutic index...
  25. pmc A novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-κB
    Katrina A Schinske
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
    Mol Cancer Ther 10:1807-17. 2011
    ..In addition, the presented results provide proof-of-principle studies as to the validity of targeting FADD-kinase activity as a novel cancer therapy strategy...
  26. pmc Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers
    Craig J Galban
    Center for Molecular Imaging and Departments of Radiology, University of Michigan, School of Medicine, Ann Arbor, Michigan 48109 0220, USA
    Clin Cancer Res 16:1542-52. 2010
    ....
  27. ncbi request reprint Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D
    Bradford A Moffat
    Department of Radiology, Center for Molecular Imaging, University of Michigan Medical School, Ann Arbor, Michigan 48109 0503, USA
    Clin Cancer Res 12:1525-32. 2006
    ..The aim of this study was to evaluate the effect of VEGF-A expression on tumor growth, perfusion, and chemotherapeutic efficacy in orthotopic 9L gliosarcomas...
  28. pmc Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas
    Thomas C Kwee
    Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    J Magn Reson Imaging 31:531-7. 2010
    ..To compare apparent diffusion coefficients (ADCs) with distributed diffusion coefficients (DDCs) in high-grade gliomas...
  29. doi request reprint Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer
    Daniel A Hamstra
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109 5010, USA
    Clin Cancer Res 16:2666-76. 2010
    ..A previous study reported radiation protection from mucosal injury with D-methionine (D-met) in preclinical evaluation; therefore, the pharmacokinetics, safety, and utility of D-met were evaluated clinically...
  30. ncbi request reprint The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies
    Daniel A Hamstra
    Department of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor 48109 0582, USA
    Mol Ther 10:916-28. 2004
    ....
  31. pmc Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment
    Craig J Galban
    Department of Radiology, University of Michigan, Center for Molecular Imaging, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 17:4751-60. 2011
    ..Our study assessed the effectiveness of the parametric response map (PRM) imaging biomarker to provide for an earlier measure of patient survival prediction...
  32. ncbi request reprint An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone
    Kuei C Lee
    Department of Radiology, and Center for Molecular Imaging, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA
    Cancer Res 67:3524-8. 2007
    ..Validation of fDM results was accomplished by histologic analysis of excised tissue. Results from this study show the capability of fDM as a biomarker for detection of bone cancer treatment efficacy, thus warranting clinical evaluation...
  33. pmc Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma
    Victor D Schepkin
    Department of Radiology, Center for Molecular Imaging, University of Michigan Medical School, Kresge II Research Building, R3028, 200 Zina Pitcher Place, Ann Arbor, MI 48109, USA
    Magn Reson Med 53:85-92. 2005
    ..This study demonstrates the possibility of Na MRI to function as a biomarker for monitoring early tumor treatment and validates the use of monitoring changes in diffusion MRI values for assessing tumor cellularity...
  34. ncbi request reprint Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy
    Kuei C Lee
    Department of Biological Chemistry, The University of Michigan Medical Center, Ann Arbor, MI 48109 0582, USA
    Clin Cancer Res 13:1839-46. 2007
    ....
  35. ncbi request reprint Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy
    Thomas L Chenevert
    Department of Radiology, Center for Molecular Imaging, University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0030, USA
    Mol Imaging 1:336-43. 2002
    ....
  36. ncbi request reprint Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study
    Daniel A Hamstra
    The Department of Radiation, The University of Michigan Medical Center, Ann Arbor, MI 48109 0648, USA
    J Neurooncol 73:225-38. 2005
    ....
  37. ncbi request reprint Dynamic imaging of emerging resistance during cancer therapy
    Kuei C Lee
    Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Res 66:4687-92. 2006
    ..Overall, this study highlights the ability of diffusion MRI to provide sensitive dynamic assessment of therapy-induced response, allowing early opportunities for optimization of therapeutic protocols...
  38. pmc Molecular imaging of the ATM kinase activity
    Terence M Williams
    Department of Radiation Oncology, Ohio State University, Columbus, Ohio, USA
    Int J Radiat Oncol Biol Phys 86:969-77. 2013
    ..We sought to create a bioluminescent reporter that dynamically and noninvasively measures ATM kinase activity in living cells and subjects...
  39. pmc DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma
    Stefanie Galban
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 7:e35857. 2012
    ..DW-MRI provided early changes to radiosensitization treatment warranting evaluation of this imaging biomarker in clinical trials...
  40. pmc Assessment of multiexponential diffusion features as MRI cancer therapy response metrics
    Benjamin A Hoff
    Department of Radiology, Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan 48109 2200, USA
    Magn Reson Med 64:1499-509. 2010
    ....
  41. pmc A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone
    Kuei C Lee
    Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA
    Neoplasia 9:1003-11. 2007
    ..Thus, the fDM imaging biomarker may provide a quantifiable therapeutic endpoint to assess response in patients with metastatic bone cancer...
  42. ncbi request reprint Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker
    Daniel E Hall
    University of Michigan, Center for Molecular Imaging and Department of Radiology, 1150 West Medical Center Drive, Ann Arbor, MI 48109 0648, USA
    Clin Cancer Res 10:7852-9. 2004
    ....
  43. pmc Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response
    Bradford A Moffat
    Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 102:5524-9. 2005
    ..Overall, fDM analysis provided an early biomarker for predicting treatment response in brain tumor patients...
  44. pmc Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma
    Daniel A Hamstra
    Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109 0648, USA
    Proc Natl Acad Sci U S A 102:16759-64. 2005
    ..Further evaluation of this technique is warranted to determine whether it may be useful in the individualization of treatment or evaluation of the response in clinical protocols...
  45. pmc Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer
    Terence M Williams
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Mol Cancer Ther 11:1193-202. 2012
    ..These results provide rationale for further testing of a treatment regimen in pancreatic cancer that combines MEK inhibition with radiation, optimally in conjunction with Akt inhibition...
  46. pmc Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand
    Mahaveer S Bhojani
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 6:e22418. 2011
    ..These studies demonstrate a potential utility of F3 peptide-based radioligands for tumor imaging with PET or SPECT techniques...
  47. pmc Enhancing Akt imaging through targeted reporter expression
    Limin Zhang
    Department of Radiation Oncology, Center for Molecular Imaging, University of Michigan, Ann Arbor, MI 48109, USA
    Mol Imaging 7:168-74. 2008
    ..Based on these results, we propose that the membrane-associated Akt reporter may be better suited for identification of novel compounds that modulate the Akt pathway by high-throughput screening...
  48. pmc A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness
    Julia M Coppola
    Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 10:363-70. 2008
    ..Additionally, this molecule inhibited proMT1-MMP processing, complete MMP-2 maturation, and invasiveness of human fibrosarcoma cells (HT1080)...
  49. pmc Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment
    Bing Ma
    Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA
    Inf Process Med Imaging 21:276-87. 2009
    ..Comparison of the experimental results with pathology shows that ADC changes can be used to evaluate early response of breast cancer treatment...
  50. ncbi request reprint Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy
    Kuei C Lee
    Department of Radiology, Center for Molecular Imaging, University of Michigan Medical School, Biomedical Sciences Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA
    Clin Cancer Res 13:443-50. 2007
    ..In this study, we evaluate the feasibility of using diffusion magnetic resonance imaging (MRI) as a reliable and quantitative measure for the early assessment of response in a breast cancer model...
  51. pmc Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom
    DARIYA MALYARENKO
    Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
    J Magn Reson Imaging 37:1238-46. 2013
    ....
  52. pmc Radiosynthesis and evaluation of 5-[125I]iodoindol-3-yl-beta-D-galactopyranoside as a beta-galactosidase imaging radioligand
    Marcian E Van Dort
    Department of Radiology, Center for Molecular Imaging, University of Michigan Medical School, Ann Arbor, MI 48109 2200, USA
    Mol Imaging 7:187-97. 2008
    ....
  53. pmc Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells
    Joseph N Contessa
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Cancer Res 68:3803-9. 2008
    ..This study provides evidence that enzymatic steps regulating N-linked glycosylation are novel targets for developing approaches to sensitize tumor cells to cytotoxic therapies...
  54. ncbi request reprint Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer
    Mahaveer S Bhojani
    Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109 0648, USA
    Cell Cycle 4:1478-81. 2005
    ..These results suggest that levels of p-FADD may be used as a prognostic biomarker for predicting survival of lung cancer patients...
  55. ncbi request reprint Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging
    Daniel A Hamstra
    Department of Radiation Oncology, University of Michigan Medical Center, 1331 East Ann Street, Ann Arbor, MI 48109, USA
    Cancer Res 66:7482-9. 2006
    ..In addition, the kinetics of oscillations were altered by pretreatment with radiation-modifying agents. These results show the use of this mouse model in enhancing our understanding of the transcriptional role of p53 in vivo...
  56. pmc A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information
    Charles R Meyer
    University of Michigan, Ann Arbor, USA
    Mol Imaging 5:16-23. 2006
    ..Overall, this approach provides a robust method for coregistration of in vivo images with histological sections and will have broad applications in the field of functional and molecular imaging...
  57. ncbi request reprint Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy
    Yong Eun Lee Koo
    University of Michigan, Michigan 48109, USA
    Appl Opt 46:1924-30. 2007
    ....
  58. ncbi request reprint Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma
    Patrick McConville
    MIR Preclinical Services, Inc, Ann Arbor, Michigan, USA
    Clin Cancer Res 13:2897-904. 2007
    ..The nestin tv-a (Ntv-a) genetically engineered mouse spontaneously develops glioma when infected with ALV-A expressing platelet-derived growth factor, resulting in autocrine platelet-derived growth factor signaling...
  59. pmc Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma
    Hanxiao Wang
    Center for Molecular Imaging, Departments of Radiation Oncology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Clin Cancer Res 19:158-69. 2013
    ..Platinum-based chemotherapy, such as cisplatin, represents the standard-of-care for ovarian cancer. However, toxicity and acquired resistance to cisplatin have proven challenging in the treatment of patients with ovarian cancer...
  60. pmc Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies
    Thomas L Chenevert
    Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
    J Magn Reson Imaging 34:983-7. 2011
    ..Validating imaging biomarkers through multicenter trials requires calibration and performance testing across sites...
  61. ncbi request reprint Imaging of proteolytic activity using a conditional cell surface receptor
    Mahaveer Swaroop Bhojani
    University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Mol Imaging 5:129-37. 2006
    ..This methodology may provide for a multimodal noninvasive real-time imaging of apoptosis and a new opportunity for high-throughput screening of cell-death-modulating therapeutic agents...
  62. pmc Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules
    Tomoko Komiyama
    Departments of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109 0606, USA
    J Biol Chem 284:15729-38. 2009
    ....
  63. pmc Noninvasive real-time imaging of apoptosis
    Bharathi Laxman
    Center for Molecular Imaging, University of Michigan Medical School, 1150 West Medical Center Drive, Medical Sciences Research Building III, Room 9303, Ann Arbor, MI 48109 0648, USA
    Proc Natl Acad Sci U S A 99:16551-5. 2002
    ....
  64. pmc A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy
    Craig J Galban
    The University of Michigan Medical School, Ann Arbor, MI, USA
    Transl Oncol 2:184-90. 2009
    ..Observations from this study have found that diffusion MRI, when assessed by PRM(ADC), has the potential to provide both prognostic and spatial information during NSOPT of head and neck cancer...
  65. ncbi request reprint Continuous arterial spin labeling using a train of adiabatic inversion pulses
    Bradford A Moffat
    Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
    J Magn Reson Imaging 21:290-6. 2005
    ....
  66. ncbi request reprint Diffusion-weighted MRI for assessment of early cancer treatment response
    Stefanie Galban
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
    Curr Pharm Biotechnol 11:701-8. 2010
    ..The utility of DW-MRI for assessing therapeutic-induced response is further evaluated on tumors residing in the brain, head and neck and bone...
  67. ncbi request reprint A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI
    Bradford A Moffat
    University of Michigan, Ann Arbor, USA
    Mol Imaging 2:324-32. 2003
    ..The flexible formulation of these nanoparticles suggests that future modifications could be accomplished allowing for their use as a targeted molecular imaging contrast agent and/or therapeutic platform for multiple indications...
  68. ncbi request reprint Evaluation of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on the 9L rat brain tumor model using MRI
    Brian D Ross
    Department of Radiology, Center for Molecular Imaging, University of Michigan, Ann Arbor, MI 48109, USA
    NMR Biomed 16:67-76. 2003
    ....
  69. pmc Noninvasive imaging of apoptosis and its application in cancer therapeutics
    Julia M Coppola
    Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Clin Cancer Res 14:2492-501. 2008
    ..Noninvasive imaging of apoptosis facilitates optimization of therapeutic protocols regarding dosing and schedule and enables identification of efficacious combination therapies...
  70. doi request reprint Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis
    Saleha B Vuyyuri
    Departments of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 2200, USA
    Clin Cancer Res 14:2161-70. 2008
    ..D-Methionine (D-Met), the dextro-isomer of the common amino acid l-methionine, has been documented to protect normal tissues from a diverse array of oxidative insults...
  71. ncbi request reprint High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer
    Mukesh K Nyati
    Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0010, USA
    Cancer Res 62:2337-42. 2002
    ..These findings suggest that the CEA promoter-enhancer strategy confers specificity while preserving activity and is worth exploring in additional animal and, potentially, clinical trials...
  72. pmc AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist
    Daniel R Rhodes
    Michigan Center for Translational Pathology, Howard Hughes Medical Institute, and Departments of Urology, and Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 5602
    Proc Natl Acad Sci U S A 106:10284-9. 2009
    ..Taken together, these observations indicate that marked AGTR1 overexpression defines a subpopulation of ER-positive, ERBB2-negative breast cancer that may benefit from targeted therapy with AGTR1 antagonists, such as losartan...
  73. pmc Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas
    Guoan Chen
    Departments of Surgery, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 102:12507-12. 2005
    ....
  74. ncbi request reprint In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice
    Linda M Kalikin
    Department of Urology, Division of Hematology and Oncology, The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0946, USA
    Cancer Biol Ther 2:656-60. 2003
    ..This model provides a controllable biological system for further investigation into the pathogenesis of metastatic prostate cancer and evaluation of new therapies...
  75. pmc Ultraviolet radiation-induced apoptosis is mediated by Daxx
    Shiyong Wu
    Department of Radiation Oncology, Division of Radiation and Cancer Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 4:486-92. 2002
    ..These results suggest that UV-induced JNK activation is not sufficient but required for induction of apoptosis...
  76. ncbi request reprint Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology
    Daniel A Hamstra
    Department of Radiation Oncology, The Center for Molecular Imaging, University of Michigan Medical Center, Ann Arbor, MI 48109 2200, USA
    J Clin Oncol 25:4104-9. 2007
    ..This review highlights the development of this technique and the state of current clinical understanding of its utility...
  77. ncbi request reprint Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells
    Christine A Billecke
    Department of Radiation Oncology, Division of Radiation and Cancer Biology, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    Oncogene 21:4481-9. 2002
    ..Inactivation of pRb may contribute to an increased sensitivity to UV radiation by attenuating repair of DNA lesions and recovery of mRNA synthesis following UV radiation...
  78. ncbi request reprint Brain cancer diagnosis and therapy with nanoplatforms
    Yong Eun Lee Koo
    Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
    Adv Drug Deliv Rev 58:1556-77. 2006
    ..The advantages of nanoparticle-based delivery and the types of nanoparticle systems under investigation are described, as well as their applications...
  79. ncbi request reprint Identification of peptides that bind to irradiated pancreatic tumor cells
    Canhui Huang
    Department of Radiation Oncology, The University of Michigan Medical School, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 62:1497-503. 2005
    ..We wished to determine if peptides identified by phage display could be used to target irradiated pancreatic cancer cells...
  80. ncbi request reprint Evaluation of cancer therapy using diffusion magnetic resonance imaging
    Brian D Ross
    University of Michigan Medical School, Ann Arbor, Michigan 48109 0648, USA
    Mol Cancer Ther 2:581-7. 2003
    ..This article provides an overview of the use of diffusion magnetic resonance imaging as a surrogate marker for quantitating treatment responsiveness in both preclinical and clinical studies...
  81. pmc Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity
    Julia M Coppola
    Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Anal Biochem 364:19-29. 2007
    ..In conclusion, we describe a customizable noninvasive technology for real-time assessment of Golgi protease activity used to identify inhibitors of furin and BACE...
  82. pmc CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature
    Zhenhua Miao
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    Proc Natl Acad Sci U S A 104:15735-40. 2007
    ..Taken together, these data suggest that CXCR7 has key functions in promoting tumor development and progression...
  83. ncbi request reprint TRAIL and anti-tumor responses
    Mahaveer Swaroop Bhojani
    Center for Molecular Imaging, Departments of Radiology, University of Michigan Ann Arbor, Michigan 48109 0648, USA
    Cancer Biol Ther 2:S71-8. 2003
    ..Only time will tell whether the search for the Holy Grail for treatment of cancer will end with TRAIL?..
  84. ncbi request reprint Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy
    Dongfang Wang
    Brain Tumor Research Center of the Department of Neurological Surgery, University of California, San Francisco, California 94143 0520, USA
    Cancer Gene Ther 12:276-83. 2005
    ..If this construct exhibits antitumor efficacy in vivo, it may have promise as an antitumor agent in humans...
  85. pmc Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance
    Victor D Schepkin
    National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL 32310, USA
    NMR Biomed 19:1035-42. 2006
    ..Overall, these experiments demonstrate the sensitivity and applicability of sodium and diffusion MRI as tools for dynamic assessment of tumor response to therapy...
  86. ncbi request reprint Synthesis and characterization of silica-embedded iron oxide nanoparticles for magnetic resonance imaging
    Fei Yan
    Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109 1055, USA
    J Nanosci Nanotechnol 4:72-6. 2004
    ..The design of the nanoparticle is universal and flexible and allows for facile addition or interchange of its active components (i.e., MRI contrast agents and targeting moiety) with photodynamic dyes...

Research Grants5